In summary, our results demonstrate that STK39 promotes the progression of HCC is dependent on PLK1-mediated activation of the ERK signaling pathway, and the STK39/PLK1/ERK1/2 axis may be a potential drug target for HCC. This evidence concerns the gene MAPK3 and hepatocellular carcinoma.